Methylene blue—curcumin analog for the treatment of alzheimer's disease

• US 7,723,515 B1
• Filed: 01/26/2009
• Issued: 05/25/2010
• Est. Priority Date: 01/26/2009
• Status: Active Grant

• Current Assignee: Codman & Shurtleff Incorporated (Johnson & Johnson)
• Original Assignee: Codman & Shurtleff Incorporated (Johnson & Johnson)
• Inventors: DiMauro, Thomas M.
• Primary Examiner(s): Habte; Kahsay T
• Application Number:
  US12/359,713
• Time in Patent Office: 484 Days
• Field of Search: 544/37
• US Class Current: 544/37
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 279/28 with other substituents attached to the ring system

Abstract

A methylene blue—curcumin hybrid useful in treating Alzheimer'"'"'s Disease.

Claims

1. 2,6-bis(4′

, 4″

dihydroxyphenyl), 3,7-bis(dimethylamino)-phenazathionium chloride.